

# PHARMA RELATIONS

## Nicholas Hall Award for "OMNi-BiOTiC® *HETOX*"

12.04.2017 12:13

Great success for the Graz Institute Allergosan: The probiotic "Omni-Biotic Hetox", a dietary food for the treatment of liver function disorders, was awarded the international Nicholas Hall Award as Europe-wide OTC innovation of the year 2016.



Institut-Allergosan-Managing Director Mag. Anita Frauwallner with Marketing Director Mag. Christian Gsöll (left) and Nicholas Hall

Around 30 percent of the population suffer from liver problems, and contrary to popular belief that alcohol would damage the liver, the number of patients with non-alcoholic fatty liver disease is "drastically" increasing, the Allergosan Institute says. In particular, the consumption of sugar, fat, numerous medications, but also various viral diseases could massively affect the function of the liver – and this often leads to liver cancer.

With the probiotic "Omni-Biotic Hetox," developed by the Graz-based organization, which specializes in the research and development of products from natural substances such as probiotic bacteria, plant extracts and minerals, a team of the Medical University of Graz led by Prof. Dr. Vanessa Stadlbauer-Köllner clearly demonstrated that some special intestinal bacteria can influence liver function and resulting infections. "In the placebo-controlled study, the liver function of those who took the probiotic significantly improved," summarizes Prof. Stadlbauer-Köllner.

The study has already attracted enormous interest from hepatologists around the world: At the prestigious "Liver Week" of the American Association for the Study of Liver Diseases (AASLD), the work was presented and recognized among 10,000 submitted studies with an outstanding "Poster of Distinction".

This was followed by the award of the prestigious Nicholas Hall OTC Marketing Award for the most innovative product of 2016 in Europe: "This is a special honour and a huge success for us," says Mag. Anita Frauwallner, Head of the Institut Allergosan. "The fact that our product 'Omni-Biotic Hetox' receives such an award for the treatment of liver disease not only highlights the increasing importance of medically relevant probiotics – even more pleasing is the international recognition of our Company that has been involved in researching the gut and its microbiome for 25 years. We have already been able to show several times that intestinal bacteria can positively control our entire organism far beyond the digestive tract."

\*This article has been translated from German to English

<https://www.pharma-relations.de/news/europas-innovativstes-otc-produkt-kommt-aus-oesterreich>